Donald L. Siegel, MD, PhD
Donald L. Siegel, MD, PhD
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Department: Pathology and Laboratory Medicine
Contact information
510 Stellar-Chance Laboratories
422 Curie Blvd.
Philadelphia, PA 19104
422 Curie Blvd.
Philadelphia, PA 19104
Office: (215) 898-9655
Fax: (215) 573-3127
Fax: (215) 573-3127
Email:
SIEGELD@MAIL.MED.UPENN.EDU
SIEGELD@MAIL.MED.UPENN.EDU
Publications
Links
Search PubMed for articles
Division of Transfusion Medicine
Clinical/Research Fellowship in Transfusion Medicine
Immunology graduate group faculty webpage.
Search PubMed for articles
Division of Transfusion Medicine
Clinical/Research Fellowship in Transfusion Medicine
Immunology graduate group faculty webpage.
Education:
Sc.B. (Biophysics)
Brown University, 1977.
Ph.D. (Biophysics)
Harvard University, 1983.
M.D.
University of Pennsylvania, 1987.
Permanent linkSc.B. (Biophysics)
Brown University, 1977.
Ph.D. (Biophysics)
Harvard University, 1983.
M.D.
University of Pennsylvania, 1987.
Description of Research Expertise
Research InterestsProduction and characterization of pathogenic human monoclonal auto- and alloantibodies
Research Summary
My laboratory is interested in characterizing the human immune response to auto- and alloantigens on a molecular level in order to understand more about human immune repertoire development. Our goal is to use this information to develop specific therapeutic agents that down-regulate immune responses in the settings of autoimmune disease such as immune hemolytic anemias and thrombocytopenias, transfusion reactions, hemolytic disease of the newborn, and acute rejection of solid organ allografts.
To approach these problems experimentally, we have combined Fab/phage-display technology with a novel cell-surface panning method to isolate large arrays of clinically significant human monoclonal antibodies from individual patients. This approach has enabled us to study the genetic and immunological properties of pathogenic auto- and alloantibodies.
Description of Clinical Expertise
transfusion medicine, blood banking, apheresis, hematopoietic stem cell collection/processingSelected Publications
Siegel, D.L.: “The Evolving Role of Apheresis in Cellular Therapies” Webinar, Highlights of the 2011 American Society for Apheresis Meeting October 2011.Braganza A., Wallace K., Pell L., Parrish C.R., Siegel D.L., Mason N.J.: Generation and validation of canine single chain Fragment variable phage display libraries. Veterinary Immunol & Immunopathol 139: 27-40, 2011.
Zhao A., Nunez-Cruz S., Li C., Coukos G., Siegel D.L., Scholler N.: Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform. Journal of Immunological Methods 363: 221-232, 2011.
Nazha A., Cook R., Vogl D.T., Mangan P.A., Gardler M., Hummel K., Cunningham K., Luger S.M., Porter D.L., Shuster S., O’Doherty U., Siegel D., Stadtmauer E.A.: Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen. Bone Marrow Transplantation advance online publication: 1-5, 2010.
Yunk L., Ostertag E., Thiboutot M., Kacir S., Bdeir K., Siegel D.L.: Developing a mouse model for antibody-mediated thrombotic thrombocytopenic purpura using antibody phage display. 12th Annual Phage Display of Antibodies and Peptides, PEGS Protein Engineering Summit, Boston, MA. 2010.
Mangalmurti N.S., Chatterjee S., Chen G. Anderson E., Mohammed A., Siegel D.L., Schmidt A.M., Albelda S.M., Lee J.S.: Advanced glycation endproducts on stored erythrocytes increase endothelial reactive oxygen species generation through interaction with RAGE. Transfusion 50: 2352-2361, 2010.
Siegel, D.L., Quillen, K.: Transfusion Medicine. ASH Self-Assessment Program, 4th edition. Gregory, S.A. and McCrae, K.R. (eds.). American Society for Hematology, 2010.
Yamagami J., Payne A., Kacir S., Ishii K., Siegel D.L., Stanley J.R.: Homologous regions of autoantibody heavy chain complementarity-determining region 3 (H-CDR3) in patients with pemphigus cause pathogenicity. Journal of Clinical Investigation 120: 4111-4117, 2010.
Yunk L., Ostertag E., Thiboutot M., Kacir S., Bdeir K., Siegel D.L.: Developing a mouse model for antibody-mediated thrombotic thrombocytopenic purpura using antibody phage display. 12th Annual Phage Display of Antibodies and Peptides, PEGS Protein Engineering Summit, Boston, MA 2010.
Yamagami J., Payne A.S., Kacir S., Ishii K., Siegel D.L., Stanley J.R.: Modifying the heavy chain third complementarity determining regions (H-CDR3) of pemphigus antibody to prevent pathogenicity but not binding suggests a novel approach to targeted therapy. J Invest Dermatol 130: S17, 2010.